Revvity, Inc.

{
  "main_header": {
    "sid": 1159064,
    "name": "Revvity, Inc.",
    "stock_name": "Revvity, Inc.",
    "full_name": "Revvity, Inc.",
    "name_url": "stocks-analysis/revvity-inc",
    "exchange": 1,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "116.73",
    "chg": 23.85,
    "chgp": "25.68%",
    "dir": 1,
    "prev_price": "92.88",
    "mcapval": "13,211.66",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US7140461093",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "2.79 M",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/revvity-inc-1159064-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/revvity-inc-stock-downgraded-to-sell-amid-declining-sales-and-high-valuation-3775247",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/RevvityInc_mojoScore_3775247.png",
        "date": "2025-12-30 15:36:32",
        "description": "Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in its valuation grade. Key financial metrics reveal challenges, including a decline in net sales and operating profit, alongside rising raw material costs and a high debt-equity ratio, impacting its market position."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3673408",
        "imagepath": "",
        "date": "2025-11-05 11:10:57",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41.\n\nFurthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state...."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3670602",
        "imagepath": "",
        "date": "2025-11-04 11:16:55",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on its current metrics, including a P/E ratio of 33, a Price to Book Value of 1.42, and an EV to EBITDA ratio of 15.29. In comparison, peers such as Hologic, Inc. have a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is also considered very expensive with a P/E of 34.28.\n\nThe stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -16.70% compared to the S&P 500's 16.30%, and a three-year return of -27.07% versus 76.66% for the index. This underperformance further supports the conclusion that Revvity, Inc. is currently overvalued in the market...."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3666170",
        "imagepath": "",
        "date": "2025-11-03 11:16:21",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its key financial metrics, including a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, peers such as Hologic, Inc. and Align Technology, Inc. have more favorable valuations with P/E ratios of 21.83 and 20.46, respectively, suggesting that Revvity's stock is priced at a premium relative to its industry counterparts.\n\nAdditionally, Revvity has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's positive return of 16.30%. This underperformance, alongside its elevated valuation ratios, reinforces the conclusion that Revvity, Inc. is currently overvalued...."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3664303",
        "imagepath": "",
        "date": "2025-11-02 11:09:23",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, all of which suggest that the stock price may not be justified by its earnings growth prospects. In comparison, The Cooper Cos., Inc. has a higher P/E of 34.28, while Align Technology, Inc. shows a much lower P/E of 20.46, highlighting the disparity in valuation among peers.\n\nRecent stock performance further reinforces this valuation concern, as Revvity, Inc. has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's 16.30%. This trend of negative returns over multiple periods, including a 1-year return of -21.08% versus the S&P 500's 19.89%, suggests that investor sentiment may be shifting away fr..."
      }
    ],
    "total": 20,
    "sid": "1159064",
    "stock_news_url": "https://www.marketsmojo.com/news/revvity-inc-1159064"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs

2025-12-30 15:36:32

Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently experienced a change in its valuation grade. Key financial metrics reveal challenges, including a decline in net sales and operating profit, alongside rising raw material costs and a high debt-equity ratio, impacting its market position.

Read full news article

Is Revvity, Inc. overvalued or undervalued?

2025-11-05 11:10:57

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41. Furthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state....

Read full news article

Is Revvity, Inc. overvalued or undervalued?

2025-11-04 11:16:55

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on its current metrics, including a P/E ratio of 33, a Price to Book Value of 1.42, and an EV to EBITDA ratio of 15.29. In comparison, peers such as Hologic, Inc. have a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is also considered very expensive with a P/E of 34.28. The stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -16.70% compared to the S&P 500's 16.30%, and a three-year return of -27.07% versus 76.66% for the index. This underperformance further supports the conclusion that Revvity, Inc. is currently overvalued in the market....

Read full news article

Is Revvity, Inc. overvalued or undervalued?

2025-11-03 11:16:21

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its key financial metrics, including a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, peers such as Hologic, Inc. and Align Technology, Inc. have more favorable valuations with P/E ratios of 21.83 and 20.46, respectively, suggesting that Revvity's stock is priced at a premium relative to its industry counterparts. Additionally, Revvity has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's positive return of 16.30%. This underperformance, alongside its elevated valuation ratios, reinforces the conclusion that Revvity, Inc. is currently overvalued....

Read full news article

Is Revvity, Inc. overvalued or undervalued?

2025-11-02 11:09:23

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, all of which suggest that the stock price may not be justified by its earnings growth prospects. In comparison, The Cooper Cos., Inc. has a higher P/E of 34.28, while Align Technology, Inc. shows a much lower P/E of 20.46, highlighting the disparity in valuation among peers. Recent stock performance further reinforces this valuation concern, as Revvity, Inc. has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's 16.30%. This trend of negative returns over multiple periods, including a 1-year return of -21.08% versus the S&P 500's 19.89%, suggests that investor sentiment may be shifting away fr...

Read full news article

View All News